Masahiro Ishizuka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masahiro Ishizuka has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Tomoya Tateishi
Department of Respiratory Medicine, Institute of Science Tokyo Hospital, Tokyo, Japan
4 shared publications - Tsukasa Okamoto
Department of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan; Center for Personalized Medicine for Healthy Aging, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
4 shared publications - Yasunari Miyazaki
Department of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan
4 shared publications Junichi Aiboshi
Trauma and Acute Critical Care Center, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
3 shared publications- Kunihiko Takahashi
Department of Biostatistics, M&D Data Science Center, Institute of Science Tokyo, Tokyo, Japan
3 shared publications - Tatsuhiko Anzai
Department of Biostatistics, M&D Data Science Center, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan
3 shared publications
Latest Publications
- 24 September 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1146-1152
Cluster analysis of seasonal KL-6 variations in interstitial lung diseases
- 24 September 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1146-1152
Cluster analysis of seasonal KL-6 variations in interstitial lung diseases
- 10 September 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1093-1099
Impact of medications on lung function in fibrotic hypersensitivity pneumonitis
- 10 September 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1093-1099
Impact of medications on lung function in fibrotic hypersensitivity pneumonitis
- 27 March 2023
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 41, 103430
Enhancing Therapeutic Effects of Photodynamic Therapy with 5-Aminolevulinic Acid Using Polymeric Iron Chelators
- 27 March 2023
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 41, 103430
Enhancing Therapeutic Effects of Photodynamic Therapy with 5-Aminolevulinic Acid Using Polymeric Iron Chelators
- 1 June 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (6) , 857-863
Predictors associated with clinical improvement of SARS-CoV-2 pneumonia
- 1 June 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (6) , 857-863
Predictors associated with clinical improvement of SARS-CoV-2 pneumonia
- 1 February 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (2) , 284-290
MuLBSTA score is a useful tool for predicting COVID-19 disease behavior
- 1 February 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (2) , 284-290
MuLBSTA score is a useful tool for predicting COVID-19 disease behavior
- 15 January 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (2) , 355-365
IL-17A–Secreting Memory γδ T Cells Play a Pivotal Role in Sensitization and Development of Hypersensitivity Pneumonitis
Hypersensitivity pneumonitis (HP) typically presents with interstitial inflammation and granulomas induced by an aberrant immune response to inhaled Ags in sensitized individuals. Although IL-17A is involved in the development of HP, the cellular sources of IL-17A and the mechanisms by which IL-17A contributes to granuloma formation remain unclear. Recent studies report that γδ T cells produce IL-17A and exhibit memory properties in various diseases. Therefore, we focused on IL-17A–secreting memory γδ T cells in the sensitization phase and aimed to elucidate the mechanisms by which IL-17A contributes to granuloma formation in HP. We induced a mouse model of HP using pigeon dropping extract (PDE) in wild-type and IL-17A knockout (IL-17A−/−) mice. IL-17A−/− mice exhibited reduced granulomatous areas, attenuated aggregation of CD11b+ alveolar macrophages, and reduced levels of CCL2, CCL4, and CCL5 in the bronchoalveolar lavage fluid. Among IL-17A+ cells, more γδ T cells than CD4+ cells were detected after intranasal PDE administration. Interestingly, the expansion of IL-17A–secreting Vγ4+ or Vγ1−Vγ4− cells of convalescent mice was enhanced in response to the sensitizing Ag. Additionally, coculture of macrophages with PDE and Vγ4+ cells purified from PDE-exposed convalescent mice produced significantly more IL-17A than coculture with Vγ4+ cells from naive mice. Our findings demonstrate that in the sensitization phase of HP, IL-17A–secreting memory γδ T cells play a pivotal role. Furthermore, we characterized the IL-17A/CCL2, CCL4, CCL5/CD11b+ alveolar macrophage axis, which underlies granuloma formation in HP. These findings may lead to new clinical examinations or therapeutic targets for HP. Key Points IL-17A is produced mainly by γδ T cells in hypersensitivity pneumonitis (HP). The IL-17A/chemokines/CD11b+ alveolar macrophage axis underlies development of HP. Memory responses of γδ T cells are involved in sensitization and development of HP.
- 15 January 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (2) , 355-365
IL-17A–Secreting Memory γδ T Cells Play a Pivotal Role in Sensitization and Development of Hypersensitivity Pneumonitis
Hypersensitivity pneumonitis (HP) typically presents with interstitial inflammation and granulomas induced by an aberrant immune response to inhaled Ags in sensitized individuals. Although IL-17A is involved in the development of HP, the cellular sources of IL-17A and the mechanisms by which IL-17A contributes to granuloma formation remain unclear. Recent studies report that γδ T cells produce IL-17A and exhibit memory properties in various diseases. Therefore, we focused on IL-17A–secreting memory γδ T cells in the sensitization phase and aimed to elucidate the mechanisms by which IL-17A contributes to granuloma formation in HP. We induced a mouse model of HP using pigeon dropping extract (PDE) in wild-type and IL-17A knockout (IL-17A−/−) mice. IL-17A−/− mice exhibited reduced granulomatous areas, attenuated aggregation of CD11b+ alveolar macrophages, and reduced levels of CCL2, CCL4, and CCL5 in the bronchoalveolar lavage fluid. Among IL-17A+ cells, more γδ T cells than CD4+ cells were detected after intranasal PDE administration. Interestingly, the expansion of IL-17A–secreting Vγ4+ or Vγ1−Vγ4− cells of convalescent mice was enhanced in response to the sensitizing Ag. Additionally, coculture of macrophages with PDE and Vγ4+ cells purified from PDE-exposed convalescent mice produced significantly more IL-17A than coculture with Vγ4+ cells from naive mice. Our findings demonstrate that in the sensitization phase of HP, IL-17A–secreting memory γδ T cells play a pivotal role. Furthermore, we characterized the IL-17A/CCL2, CCL4, CCL5/CD11b+ alveolar macrophage axis, which underlies granuloma formation in HP. These findings may lead to new clinical examinations or therapeutic targets for HP. Key Points IL-17A is produced mainly by γδ T cells in hypersensitivity pneumonitis (HP). The IL-17A/chemokines/CD11b+ alveolar macrophage axis underlies development of HP. Memory responses of γδ T cells are involved in sensitization and development of HP.
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Open Access Emergency Medicine
- Vol. 13, 207-211
An Experience of Multiple Hematomas in a Coronavirus Disease-19 Patient Administered with ART-123 and Heparin
Background: Anticoagulant therapy for patients with severe coronavirus disease (COVID-19) pneumonia is considered to improve the hypercoagulable and inflammatory state. However, bleeding complications should also be considered. Case Presentation: A 77-year-old man with a history of falls was diagnosed with COVID-19. Owing to his severe condition, he was intubated and transferred to our hospital for intensive care. Favipiravir, tocilizumab, unfractionated heparin, and ART-123 were administered to treat COVID-19 and manage the antithrombotic prophylaxis for paroxysmal atrial fibrillation (Af). On the 6th day after admission, a hematoma was noted on the left chest wall. Computed tomography (CT) revealed multiple hematomas, including hematomas on his chest wall and obturatorius internus muscle. Emergency angiography transcatheter embolization (TAE) was performed. The patient was transferred to another hospital 23 days after TAE, without complications. Conclusion: Our findings show that anticoagulation therapy and a history of falls induced multiple hematomas in a COVID-19 patient and that the condition was managed with TAE. When anticoagulants are considered in the management of Af and COVID-19 associated coagulopathy, it is necessary to closely monitor potential bleeding complications.
- 1 January 2021
- Published by Taylor & Francis in Open Access Emergency Medicine
- Vol. 13, 207-211
Open AccessAn Experience of Multiple Hematomas in a Coronavirus Disease-19 Patient Administered with ART-123 and Heparin
Background: Anticoagulant therapy for patients with severe coronavirus disease (COVID-19) pneumonia is considered to improve the hypercoagulable and inflammatory state. However, bleeding complications should also be considered. Case Presentation: A 77-year-old man with a history of falls was diagnosed with COVID-19. Owing to his severe condition, he was intubated and transferred to our hospital for intensive care. Favipiravir, tocilizumab, unfractionated heparin, and ART-123 were administered to treat COVID-19 and manage the antithrombotic prophylaxis for paroxysmal atrial fibrillation (Af). On the 6th day after admission, a hematoma was noted on the left chest wall. Computed tomography (CT) revealed multiple hematomas, including hematomas on his chest wall and obturatorius internus muscle. Emergency angiography transcatheter embolization (TAE) was performed. The patient was transferred to another hospital 23 days after TAE, without complications. Conclusion: Our findings show that anticoagulation therapy and a history of falls induced multiple hematomas in a COVID-19 patient and that the condition was managed with TAE. When anticoagulants are considered in the management of Af and COVID-19 associated coagulopathy, it is necessary to closely monitor potential bleeding complications.
- 14 January 2016
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 15 (3) , 731-739
Photodynamic detection of canine mammary gland tumours after oral administration of 5‐aminolevulinic acid
5‐Aminolevulinic acid (5‐ALA) is widely used in photodynamic detection (PDD) and therapy. We evaluated the pharmacokinetics of 5‐ALA‐induced porphyrins and its effectiveness in PDD in dogs with mammary gland tumours (MGTs) following oral administration. Healthy dogs and those with MGTs (nine each) were orally administered 4 mg kg−1 5‐ALA. Protoporphyrin IX (PpIX) was not detected in the plasma of healthy dogs but it peaked in dogs with MGT at 2 h after 5‐ALA administration. In the PDD study, 16 dogs with MGT were orally administered 40 mg kg−1 5‐ALA, and MGT but not normal tissue showed red fluorescence after 2–4 h. Photon counts were 6635–63 890 and 59–4011 (median, 19 943 and 919) for MGT and non‐tumour tissues, respectively. Cell density strongly correlated with PpIX photon counts of MGT tissue of the dogs (R = 0.743, P = 0.0009). We suggest that 5‐ALA‐PDD might be an effective diagnostic tool for MGTs.
- 14 January 2016
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 15 (3) , 731-739
Photodynamic detection of canine mammary gland tumours after oral administration of 5‐aminolevulinic acid
5‐Aminolevulinic acid (5‐ALA) is widely used in photodynamic detection (PDD) and therapy. We evaluated the pharmacokinetics of 5‐ALA‐induced porphyrins and its effectiveness in PDD in dogs with mammary gland tumours (MGTs) following oral administration. Healthy dogs and those with MGTs (nine each) were orally administered 4 mg kg−1 5‐ALA. Protoporphyrin IX (PpIX) was not detected in the plasma of healthy dogs but it peaked in dogs with MGT at 2 h after 5‐ALA administration. In the PDD study, 16 dogs with MGT were orally administered 40 mg kg−1 5‐ALA, and MGT but not normal tissue showed red fluorescence after 2–4 h. Photon counts were 6635–63 890 and 59–4011 (median, 19 943 and 919) for MGT and non‐tumour tissues, respectively. Cell density strongly correlated with PpIX photon counts of MGT tissue of the dogs (R = 0.743, P = 0.0009). We suggest that 5‐ALA‐PDD might be an effective diagnostic tool for MGTs.
- 15 February 2013
- Published by SPIE-Intl Soc Optical Eng
- Vol. 8579, 85790T
Optical properties of tumor tissues grown on the chorioallantoic membrane of chicken eggs measured with a double integrating sphere and inverse Monte Carlo method in the wavelength range of 350–1000 nm
Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) is an attractive method because of the shorter decay time of photosensitivity compared with PDT using other drugs. However, the optimum conditions to perform ALA-PDT, e.g., drug dose, wavelength, and irradiation dose have never been clarified. To evaluate the effectiveness of PDT using ALA and its dependence on drug dose, wavelength, and irradiation dose in the treatment of tumors, the usefulness of a tumor model prepared with tumor cells grown on the chorioallantoic membrane of chicken eggs was studied by measuring the optical properties of the tumor model. The optical properties of tumor model were measured with a double integrating sphere optical setup and inverse Monte Carlo technique in the wavelength range from 350 to 1000 nm. The spectra of absorption and reduced scattering coefficients of the tumor model grown in the chicken eggs were compared with those of the other tumor model grown in mice. The measured optical properties of the tumor model using chicken eggs were similar to those of the tumor model using mice. These results indicate that the tumor model using chicken eggs is a suitable system to investigate the effectiveness of ALA-PDT. This in vivo assay system for tumors has advantages for evaluating antitumor effect of ALA-PDT because of its convenience, rapidity, and inexpensiveness.
- 15 February 2013
- Published by SPIE-Intl Soc Optical Eng
- Vol. 8579, 85790T
Optical properties of tumor tissues grown on the chorioallantoic membrane of chicken eggs measured with a double integrating sphere and inverse Monte Carlo method in the wavelength range of 350–1000 nm
Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) is an attractive method because of the shorter decay time of photosensitivity compared with PDT using other drugs. However, the optimum conditions to perform ALA-PDT, e.g., drug dose, wavelength, and irradiation dose have never been clarified. To evaluate the effectiveness of PDT using ALA and its dependence on drug dose, wavelength, and irradiation dose in the treatment of tumors, the usefulness of a tumor model prepared with tumor cells grown on the chorioallantoic membrane of chicken eggs was studied by measuring the optical properties of the tumor model. The optical properties of tumor model were measured with a double integrating sphere optical setup and inverse Monte Carlo technique in the wavelength range from 350 to 1000 nm. The spectra of absorption and reduced scattering coefficients of the tumor model grown in the chicken eggs were compared with those of the other tumor model grown in mice. The measured optical properties of the tumor model using chicken eggs were similar to those of the tumor model using mice. These results indicate that the tumor model using chicken eggs is a suitable system to investigate the effectiveness of ALA-PDT. This in vivo assay system for tumors has advantages for evaluating antitumor effect of ALA-PDT because of its convenience, rapidity, and inexpensiveness.